Journal
JOURNAL OF PEDIATRICS
Volume 162, Issue 2, Pages 375-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2012.07.052
Keywords
-
Categories
Funding
- University of Minnesota
- Lysosomal Disease Network [NIH U54NS065768-01]
- Children's Cancer Research Fund (CCRF), MN
- Genzyme
- CCRF
- Shire
- Biomarin
- Actelion
- Amicus
- Fairview Hospitals
- Pfizer
- Protalix
Ask authors/readers for more resources
Objective To investigate whether intravenous enzyme replacement therapy (ERT) benefits cognitive function in patients with mucopolysaccharidosis type IH (Hurler syndrome) undergoing hematopoietic cell transplantation (HCT). Study design Data were obtained for 9 children treated with HCT + ERT (ERT group) and 10 children treated with HCT only (no-ERT group) from neuropsychologic evaluations before HCT and at 1-year and 2-year post-HCT follow-up. Results At 2 years after HCT, children in the ERT group lost 9.19 fewer IQ points per year compared with children in the no-ERT group (P = .031). Furthermore, the ERT group improved in nonverbal problem solving and processing, whereas the no-ERT group declined, resulting in a difference of 9.44 points per year between the 2 groups (P < .001). Conclusion ERT in association with HCT enhances cognitive outcomes, providing new evidence that ERT is a valuable addition to the standard transplantation protocol. Although the mechanism responsible for this improved outcome is unknown, both direct benefits and indirect effects must be considered. (J Pediatr 2013;162:375-80).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available